

# Juliet Compston

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/315942/publications.pdf>

Version: 2024-02-01

167  
papers

16,188  
citations

29994

54  
h-index

16127

124  
g-index

177  
all docs

177  
docs citations

177  
times ranked

14338  
citing authors

#	ARTICLE	IF	CITATIONS
1	Current Treatment of Osteoporosis and Future Prospects. , 2022, , 441-455.		0
2	Towards a cure for osteoporosis: the UK Royal Osteoporosis Society (ROS) Osteoporosis Research Roadmap. Archives of Osteoporosis, 2022, 17, 12.	1.0	5
3	UK clinical guideline for the prevention and treatment of osteoporosis. Archives of Osteoporosis, 2022, 17, 58.	1.0	146
4	Role of the Microbiome in Regulating Bone Metabolism and Susceptibility to Osteoporosis. Calcified Tissue International, 2022, 110, 273-284.	1.5	22
5	Opportunistic diagnosis of osteoporosis, fragile bone strength and vertebral fractures from routine CT scans; a review of approved technology systems and pathways to implementation. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110240.	1.2	28
6	Reducing the treatment gap in osteoporosis. Lancet Diabetes and Endocrinology,the, 2020, 8, 7-9.	5.5	18
7	Defining Very High Fracture Risk: Is <sc>FRAX</sc> Fit for Purpose?. Journal of Bone and Mineral Research, 2020, 35, 1399-1403.	3.1	13
8	Sarcopenia and Its Association with Vertebral Fractures in People Living with HIV. Calcified Tissue International, 2020, 107, 249-256.	1.5	7
9	Relationship Between Obesity and Risk of Major Osteoporotic Fracture in Postmenopausal Women: Taking Frailty Into Consideration. Journal of Bone and Mineral Research, 2020, 35, 2355-2362.	3.1	13
10	Preschool Obesity Is Associated With an Increased Risk of Childhood Fracture: A Longitudinal Cohort Study of 466,997 Children and Up to 11â€™%Years of Followâ€™up in Catalonia, Spain. Journal of Bone and Mineral Research, 2020, 35, 1022-1030.	3.1	27
11	Practical guidance for the use of bisphosphonates in osteoporosis. Bone, 2020, 136, 115330.	1.4	17
12	Opportunities and Challenges in Functional Genomics Research in Osteoporosis: Report From a Workshop Held by the Causes Working Group of the Osteoporosis and Bone Research Academy of the Royal Osteoporosis Society on October 5th 2020. Frontiers in Endocrinology, 2020, 11, 630875.	1.5	5
13	Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. Journal of Bone Oncology, 2020, 25, 100311.	1.0	27
14	HIV Infection, HIV Therapy, and Bone Health. , 2020, , 146-155.		0
15	Management of glucocorticoidâ€™induced osteoporosis: What is new?. International Journal of Rheumatic Diseases, 2019, 22, 1595-1597.	0.9	3
16	Repeating Measurement of Bone Mineral Density when Monitoring with Dual-energy X-ray Absorptiometry: 2019 ISCD Official Position. Journal of Clinical Densitometry, 2019, 22, 489-500.	0.5	27
17	Osteoporosis. Lancet, The, 2019, 393, 364-376.	6.3	1,252
18	The prevention of glucocorticoidâ€™induced osteoporosis in patients with immune thrombocytopenia receiving steroids: aâ€™British Society for Haematology Good Practice Paper. British Journal of Haematology, 2019, 185, 410-417.	1.2	10

#	ARTICLE	IF	CITATIONS
19	Glucocorticoid-induced osteoporosis: an update. <i>Endocrine</i> , 2018, 61, 7-16.	1.1	288
20	Type 2 diabetes mellitus and bone. <i>Journal of Internal Medicine</i> , 2018, 283, 140-153.	2.7	134
21	Jeffrey Lima Hayes O'Riordan: March 27, 1931 – October 9, 2017. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1-2.	3.1	25
22	The Hidden Burden of Fractures in People Living With HIV. <i>JBMR Plus</i> , 2018, 2, 247-256.	1.3	29
23	HIV and Vertebral Fractures: a Systematic Review and Metanalysis. <i>Scientific Reports</i> , 2018, 8, 7838.	1.6	25
24	Bone Histomorphometry. , 2018, , 959-973.		7
25	Cost-effective but clinically inappropriate: new NICE intervention thresholds in osteoporosis (Technology Appraisal 464). <i>Osteoporosis International</i> , 2018, 29, 1511-1513.	1.3	18
26	Progress in Publishing: Benefits for <i>JBMR</i> Authors, Reviewers, and Readers. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 423-423.	3.1	0
27	UK clinical guideline for the prevention and treatment of osteoporosis. <i>Archives of Osteoporosis</i> , 2017, 12, 43.	1.0	609
28	Safety of long-term denosumab therapy for osteoporosis. <i>Lancet Diabetes and Endocrinology</i> , the, 2017, 5, 485-487.	5.5	11
29	Addressing the Crisis in the Treatment of Osteoporosis: A Path Forward. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 424-430.	3.1	134
30	Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. <i>Journal of Clinical Densitometry</i> , 2017, 20, 8-24.	0.5	185
31	Bone-forming agents in non-responders to bisphosphonates. <i>Lancet, The</i> , 2017, 390, 1565-1566.	6.3	0
32	NOGG and NICE: New guidelines and quality standards for osteoporosis. <i>Maturitas</i> , 2017, 106, 97-98.	1.0	8
33	Bisphosphonates in osteoporosis: NICE and easy?. <i>Lancet, The</i> , 2017, 390, 2243-2244.	6.3	23
34	Access to fracture risk assessment by FRAX and linked National Osteoporosis Guideline Group (NOGG) guidance in the UK – an analysis of anonymous website activity. <i>Osteoporosis International</i> , 2017, 28, 71-76.	1.3	15
35	A Fond Farewell to <i>JBMR</i>. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 2321-2321.	3.1	0
36	The role of tenofovir alafenamide in future HIV management. <i>HIV Medicine</i> , 2016, 17, 4-16.	1.0	40

#	ARTICLE	IF	CITATIONS
37	Increase in Fracture Risk Following Unintentional Weight Loss in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1466-1472.	3.1	29
38	Ignac Fogelman: 1948â€“2016. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1785-1786.	3.1	1
39	Osteoporosis: advances in risk assessment and management. <i>Clinical Medicine</i> , 2016, 16, s121-s124.	0.8	9
40	<sc>HIV</sc> infection and bone disease. <i>Journal of Internal Medicine</i> , 2016, 280, 350-358.	2.7	60
41	Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 16-35.	3.1	491
42	SIGN Guidelines for Scotland: BMD Versus FRAX Versus QFracture. <i>Calcified Tissue International</i> , 2016, 98, 417-425.	1.5	32
43	<i>JBMR</i>'s 30th Anniversary: Cause for Celebration. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 15-15.	3.1	0
44	Obesity and fractures in postmenopausal women. <i>Current Opinion in Rheumatology</i> , 2015, 27, 414-419.	2.0	65
45	Emerging therapeutic concepts for muscle and bone preservation/building. <i>Bone</i> , 2015, 80, 150-156.	1.4	9
46	Weight change and risk of fracture in postmenopausal women. <i>BMJ, The</i> , 2015, 350, h60-h60.	3.0	2
47	International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study. <i>Osteoporosis International</i> , 2015, 26, 419-420.	1.3	36
48	HIV infection and osteoporosis. <i>BoneKEy Reports</i> , 2015, 4, 636.	2.7	30
49	Overdiagnosis of osteoporosis: fact or fallacy?. <i>Osteoporosis International</i> , 2015, 26, 2051-2054.	1.3	19
50	Emerging therapeutic concepts for muscle and bone preservation/formation. <i>Bone</i> , 2015, 80, 157-161.	1.4	2
51	FRAX-based assessment and intervention thresholdsâ€”an exploration of thresholds in women aged 50Âyears and older in the UK. <i>Osteoporosis International</i> , 2015, 26, 2091-2099.	1.3	56
52	FRAXâ€”Where are we now?. <i>Maturitas</i> , 2015, 82, 284-287.	1.0	13
53	Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 3-23.	3.1	957
54	Obesity and fractures. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2014, 58, 470-477.	1.3	46

#	ARTICLE	IF	CITATIONS
55	Osteoporosis and Fracture Risk Associated with HIV Infection and Treatment. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 769-780.	1.2	23
56	Relationship of Weight, Height, and Body Mass Index With Fracture Risk at Different Sites in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women (GLOW). <i>Journal of Bone and Mineral Research</i> , 2014, 29, 487-493.	3.1	192
57	Osteoporosis in men: who should we treat?. <i>BMJ, The</i> , 2014, 349, g4229-g4229.	3.0	0
58	Obesity, Health-Care Utilization, and Health-Related Quality of Life After Fracture in Postmenopausal Women: Global Longitudinal Study of Osteoporosis in Women (GLOW). <i>Calcified Tissue International</i> , 2014, 94, 223-231.	1.5	36
59	Relationship Between Mortality and BMI After Fracture: A Population-Based Study of Men and Women Aged ≥40 Years. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1737-1744.	3.1	45
60	Strontium ranelate lives to fight another day. <i>Maturitas</i> , 2014, 78, 75-76.	1.0	10
61	Obesity and Bone. <i>Current Osteoporosis Reports</i> , 2013, 11, 30-35.	1.5	76
62	Obesity and fractures. <i>Joint Bone Spine</i> , 2013, 80, 8-10.	0.8	20
63	Osteoporosis in the European Union: a compendium of country-specific reports. <i>Archives of Osteoporosis</i> , 2013, 8, 137.	1.0	561
64	Osteoporosis in the European Union: medical management, epidemiology and economic burden. <i>Archives of Osteoporosis</i> , 2013, 8, 136.	1.0	1,932
65	Predictive value of FRAX for fracture in obese older women. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 188-195.	3.1	39
66	Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. <i>Maturitas</i> , 2013, 75, 392-396.	1.0	264
67	The association between fracture site and obesity in men: A population-Based cohort study. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1771-1777.	3.1	103
68	Obesity, Diabetes, and Fractures. , 2013, , 1331-1348.		3
69	Recent advances in the risk assessment and treatment of osteoporosis. <i>Clinical Medicine</i> , 2012, 12, s2-s5.	0.8	0
70	Histomorphometric interpretation of bone biopsies for the evaluation of osteoporosis treatment. <i>BoneKey Reports</i> , 2012, 1, 47.	2.7	4
71	Bisphosphonates in the treatment of osteoporosis. <i>BMJ, The</i> , 2012, 344, e3211-e3211.	3.0	32
72	Effect of co-morbidities on fracture risk: Findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). <i>Bone</i> , 2012, 50, 1288-1293.	1.4	129

#	ARTICLE	IF	CITATIONS
73	Differing risk profiles for individual fracture sites: Evidence from the global longitudinal study of osteoporosis in women (GLOW). <i>Journal of Bone and Mineral Research</i> , 2012, 27, 1907-1915.	3.1	43
74	The association between fracture and obesity is site-dependent: A population-based study in postmenopausal women. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 294-300.	3.1	261
75	Bisphosphonate therapy for osteoporosis: The long and short of it. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 240-242.	3.1	38
76	The use of combination therapy in the treatment of postmenopausal osteoporosis. <i>Endocrine</i> , 2012, 41, 11-18.	1.1	28
77	A comparison of case-finding strategies in the UK for the management of hip fractures. <i>Osteoporosis International</i> , 2012, 23, 907-915.	1.3	47
78	Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2011, 10, 470-476.	0.3	15
79	Obesity Is Not Protective against Fracture in Postmenopausal Women: GLOW. <i>American Journal of Medicine</i> , 2011, 124, 1043-1050.	0.6	446
80	Age-Related Changes in Bone Remodelling and Structure in Men: Histomorphometric Studies. <i>Journal of Osteoporosis</i> , 2011, 2011, 1-4.	0.1	15
81	Clinical Question: What is the best approach to managing glucocorticoid-induced osteoporosis?. <i>Clinical Endocrinology</i> , 2011, 74, 547-550.	1.2	22
82	Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. <i>Osteoporosis International</i> , 2011, 22, 2951-2961.	1.3	102
83	Osteoporosis: burden, health care provision and opportunities in the EU. <i>Archives of Osteoporosis</i> , 2011, 6, 59-155.	1.0	459
84	Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: estimations from a disease model. <i>Archives of Osteoporosis</i> , 2011, 6, 179-188.	1.0	69
85	Bone Histomorphometry. , 2011, , 845-859.		2
86	Obesity and fractures in postmenopausal women. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 292-297.	3.1	233
87	The US FRAX® filter: avoiding confusion or hindering progress?. <i>Osteoporosis International</i> , 2010, 21, 885-885.	1.3	10
88	Comparison of Changes in Bone Density and Turnover with Abacavir+Lamivudine versus Tenofovir+Emtricitabine in HIV-1 Infected Adults: 48-Week Results from the ASSERT Study. <i>Clinical Infectious Diseases</i> , 2010, 51, 963-972.	2.9	370
89	Management of glucocorticoid-induced osteoporosis. <i>Nature Reviews Rheumatology</i> , 2010, 6, 82-88.	3.5	157
90	Low rates of treatment in postmenopausal women with a history of low trauma fractures: results of audit in a Fracture Liaison Service. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2010, 103, 33-40.	0.2	34

#	ARTICLE	IF	CITATIONS
91	Differential effects of strontium ranelate, bisphosphonates and teriparatide on bone microstructure: Fact or fiction?. <i>IBMS BoneKEy</i> , 2010, 7, 414-417.	0.1	0
92	Osteoporosis: Social and Economic Impact. <i>Radiologic Clinics of North America</i> , 2010, 48, 477-482.	0.9	90
93	Impact of Prevalent Fractures on Quality of Life: Baseline Results From the Global Longitudinal Study of Osteoporosis in Women. <i>Mayo Clinic Proceedings</i> , 2010, 85, 806-813.	1.4	159
94	Transplantation Osteoporosis. , 2010, , 443-452.		1
95	Bisphosphonate Associated Osteonecrosis of the Jaw. <i>Journal of Rheumatology</i> , 2009, 36, 478-490.	1.0	173
96	Recent advances in the management of osteoporosis. <i>Clinical Medicine</i> , 2009, 9, 565-569.	0.8	18
97	NICE: its influence in treating osteoporosis in the UK and beyond. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2009, 1, 63-66.	1.2	1
98	Bone health in HIV infection. <i>British Medical Bulletin</i> , 2009, 92, 123-133.	2.7	12
99	Monitoring osteoporosis treatment. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 781-788.	1.4	51
100	The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. <i>Osteoporosis International</i> , 2009, 20, 1107-1116.	1.3	79
101	Could Strontium Ranelate Have a Synergistic Role in the Treatment of Osteoporosis?. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1354-1357.	3.1	35
102	Clinical and therapeutic aspects of osteoporosis. <i>European Journal of Radiology</i> , 2009, 71, 388-391.	1.2	36
103	Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. <i>Maturitas</i> , 2009, 62, 105-108.	1.0	346
104	Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. <i>Osteoporosis International</i> , 2008, 19, 1247-1250.	1.3	26
105	The cost-effectiveness of alendronate in the management of osteoporosis. <i>Bone</i> , 2008, 42, 4-15.	1.4	136
106	Compliance in osteoporosis. <i>Independent Nurse</i> , 2008, 2008, .	0.0	0
107	Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. <i>Journal of Rheumatology</i> , 2008, 35, 1391-7.	1.0	120
108	Treatments for Osteoporosis â€” Looking beyond the HORIZON. <i>New England Journal of Medicine</i> , 2007, 356, 1878-1880.	13.9	36

#	ARTICLE	IF	CITATIONS
109	Does parathyroid hormone treatment affect fracture risk or bone mineral density in patients with osteoporosis?. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 324-325.	3.2	2
110	Skeletal actions of intermittent parathyroid hormone: Effects on bone remodelling and structure. <i>Bone</i> , 2007, 40, 1447-1452.	1.4	141
111	Parathyroid hormone (1-84): new clinical perspectives for treating patients at high-risk of fractures. <i>Expert Review of Obstetrics and Gynecology</i> , 2007, 2, 577-585.	0.4	0
112	Bone Remodeling Rate and Remodeling Balance Are Not Co-Regulated in Adulthood: Implications for the Use of Activation Frequency as an Index of Remodeling Rate. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 1031-1036.	3.1	25
113	Non-compliance: the Achilles' heel of anti-fracture efficacy. <i>Osteoporosis International</i> , 2007, 18, 711-719.	1.3	143
114	Over-suppression of bone turnover: Does it exist?. <i>Current Osteoporosis Reports</i> , 2007, 5, 179-185.	1.5	5
115	Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis. <i>Current Rheumatology Reports</i> , 2007, 9, 78-84.	2.1	36
116	Compliance with osteoporosis therapy is the weakest link. <i>Lancet, The</i> , 2006, 368, 973-974.	6.3	86
117	Bone quality: what is it and how is it measured?. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2006, 50, 579-585.	1.3	89
118	Osteoclastogenesis during Infective Exacerbations in Patients with Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 306-311.	2.5	51
119	Osteoporosis and its management. <i>BMJ: British Medical Journal</i> , 2006, 333, 1251-1256.	2.4	191
120	How to manage osteoporosis after the menopause. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 1007-1019.	1.4	20
121	Recombinant Parathyroid Hormone in the Management of Osteoporosis. <i>Calcified Tissue International</i> , 2005, 77, 65-71.	1.5	16
122	Prevention of vertebral fractures by strontium ranelate in postmenopausal women with osteoporosis. <i>Osteoporosis International</i> , 2005, 16, S4-S6.	1.3	13
123	Guidelines for the management of osteoporosis: the present and the future. <i>Osteoporosis International</i> , 2005, 16, 1173-1176.	1.3	23
124	Strontium Ranelate Reduces the Risk of Nonvertebral Fractures in Postmenopausal Women with Osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2816-2822.	1.8	955
125	Influence of estrogen therapy at conventional and high doses on the degree of mineralization of iliac bone tissue: a quantitative microradiographic analysis in postmenopausal women. <i>Bone</i> , 2005, 36, 562-567.	1.4	51
126	Bone Histomorphometry and Its Application to Transplantation Bone Disease. , 2005, , 159-171.		0



#	ARTICLE	IF	CITATIONS
127	US and UK guidelines for glucocorticoid-induced osteoporosis: Similarities and differences. <i>Current Rheumatology Reports</i> , 2004, 6, 66-69.	2.1	46
128	Osteoporosis after liver transplantation. <i>Liver Transplantation</i> , 2003, 9, 321-330.	1.3	100
129	Editorial: The skeletal effects of liver transplantation in children. <i>Liver Transplantation</i> , 2003, 9, 371-372.	1.3	8
130	Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: long-term follow-up of a prospective study. <i>British Journal of Haematology</i> , 2003, 121, 462-468.	1.2	68
131	Glucocorticoid-Induced Osteoporosis. <i>Hormone Research in Paediatrics</i> , 2003, 60, 77-79.	0.8	19
132	Is fracture risk increased in patients with coeliac disease?. <i>Gut</i> , 2003, 52, 459-460.	6.1	31
133	Osteoporosis in inflammatory bowel disease. <i>Gut</i> , 2003, 52, 63-64.	6.1	42
134	Osteoporosis associated with gastrointestinal diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 841-843.	0.8	3
135	Can biochemical markers be used to screen patients with inflammatory bowel disease for osteoporosis?. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 587-589.	0.8	9
136	Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. <i>Journal of Hepatology</i> , 2002, 37, 93-100.	1.8	89
137	Effects of estrogen on collagen synthesis by cultured human osteoblasts depend on the rate of cellular differentiation. <i>Journal of Cellular Biochemistry</i> , 2002, 86, 251-257.	1.2	26
138	Combination therapy for postmenopausal osteoporosis. <i>Clinical Endocrinology</i> , 2002, 56, 565-569.	1.2	25
139	Effects of a single infusion of pamidronate prior to liver transplantation: a bone histomorphometric study. <i>Transplant International</i> , 2002, 15, 290-295.	0.8	23
140	Sex Steroids and Bone. <i>Physiological Reviews</i> , 2001, 81, 419-447.	13.1	431
141	Colocalization of Glucocorticoid and Mineralocorticoid Receptors in Human Bone. <i>Journal of Bone and Mineral Research</i> , 2001, 16, 1496-1504.	3.1	88
142	Incidence of vertebral fractures in the first three months after orthotopic liver transplantation. <i>European Journal of Gastroenterology and Hepatology</i> , 2000, 12, 931-935.	0.8	107
143	Mechanism of Bone Loss After Liver Transplantation: A Histomorphometric Analysis. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 281-287.	3.1	68
144	Bone Densitometry and Clinical Decision Making. <i>Journal of Clinical Densitometry</i> , 1999, 2, 5-9.	0.5	3

#	ARTICLE	IF	CITATIONS
145	The role of SERMs in the management of postmenopausal osteoporosis. <i>Journal of Endocrinological Investigation</i> , 1999, 22, 646-652.	1.8	2
146	Selective oestrogen receptor modulators: potential therapeutic applications. <i>Clinical Endocrinology</i> , 1998, 48, 389-391.	1.2	18
147	International conference on biomedical aspects of aging research. <i>Aging Clinical and Experimental Research</i> , 1998, 10, 141-177.	1.4	2
148	Detection of osteoporosis in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 1997, 9, 931-933.	0.8	14
149	Prevention and Management of Osteoporosis. <i>Drugs</i> , 1997, 53, 727-735.	4.9	75
150	7 Hormone replacement therapy. <i>Bailliere's Clinical Rheumatology</i> , 1997, 11, 583-596.	1.0	11
151	Cortical Remodeling Following Suppression of Endogenous Estrogen with Analogs of Gonadotrophin Releasing Hormone. <i>Journal of Bone and Mineral Research</i> , 1997, 12, 1231-1240.	3.1	22
152	Distribution of matrix metalloproteinases and their inhibitor, TIMP-1, in developing human osteophytic bone. <i>Journal of Anatomy</i> , 1997, 191, 39-48.	0.9	60
153	Early increase in plasma parathyroid hormone levels following liver transplantation. <i>Journal of Hepatology</i> , 1996, 25, 715-718.	1.8	62
154	Bone mineral mass consolidation in young British adults. <i>Journal of Bone and Mineral Research</i> , 1996, 11, 264-274.	3.1	57
155	Assessment of cancellous bone structure: Comparison of strut analysis, trabecular bone pattern factor, and marrow space star volume. <i>Journal of Bone and Mineral Research</i> , 1996, 11, 955-961.	3.1	97
156	Expression of Platelet Derived Growth Factor- $\alpha$ and Transforming Growth Factor $\beta$ 1 Mrna in Heterotopic Bone. <i>Clinical Science</i> , 1995, 89, 10P-10P.	0.0	0
157	Expression of Collagenase and other Matrix Metalloproteinases in Human Bone in Vivo. <i>Clinical Science</i> , 1995, 89, 10P-11P.	0.0	0
158	The role of vitamin D and calcium supplementation in the prevention of osteoporotic fractures in the elderly. <i>Clinical Endocrinology</i> , 1995, 43, 393-405.	1.2	22
159	Sex hormones and bone mineral density in elderly men. <i>Bone and Mineral</i> , 1993, 20, 133-140.	2.0	180
160	Osteomalacia. , 1993, , 63-82.		0
161	Paget's disease. , 1993, , 83-114.		0
162	The hypercalcaemic patient. , 1993, , 115-140.		0

#	ARTICLE	IF	CITATIONS
163	The hypocalcaemic patient. , 1993, , 141-155.		0
164	Rare bone disorders presenting as fractures. , 1993, , 156-163.		0
165	Low bone turnover state in primary biliary cirrhosis. Hepatology, 1987, 7, 137-142.	3.6	131
166	Reduced plasma half-life of radio-labelled 25-hydroxyvitamin D3 in subjects receiving a high-fibre diet. British Journal of Nutrition, 1983, 49, 213-216.	1.2	91
167	Comparison of the Appearance of Radiolabelled Vitamin D3 and 25-Hydroxy-Vitamin D3 in the Chylomicron Fraction of Plasma after Oral Administration in Man. Clinical Science, 1981, 60, 241-243.	1.8	37